Analyses of cost-effectiveness of migraine therapies should consider multiple measures.
Silberstein
Stephen D
SD
D003362:Cost-Benefit Analysis / Q000379:methods; D004334:Drug Administration Schedule; D023381:Endpoint Determination / Q000379:methods; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy / Q000191:economics*; D012008:Recurrence; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
D017366:Serotonin Receptor Agonists